Sagimet Biosciences Inc
NASDAQ:SGMT

Watchlist Manager
Sagimet Biosciences Inc Logo
Sagimet Biosciences Inc
NASDAQ:SGMT
Watchlist
Price: 4.76 USD 5.78% Market Closed
Market Cap: 144.7m USD
Have any thoughts about
Sagimet Biosciences Inc?
Write Note

Intrinsic Value

SGMT's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one SGMT stock under the Base Case scenario is 3.12 USD. Compared to the current market price of 4.76 USD, Sagimet Biosciences Inc is Overvalued by 34%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SGMT Intrinsic Value
3.12 USD
Overvaluation 34%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Sagimet Biosciences Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for SGMT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about SGMT?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Sagimet Biosciences Inc

Provide an overview of the primary business activities
of Sagimet Biosciences Inc.

What unique competitive advantages
does Sagimet Biosciences Inc hold over its rivals?

What risks and challenges
does Sagimet Biosciences Inc face in the near future?

Has there been any significant insider trading activity
in Sagimet Biosciences Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Sagimet Biosciences Inc.

Provide P/S
for Sagimet Biosciences Inc.

Provide P/E
for Sagimet Biosciences Inc.

Provide P/OCF
for Sagimet Biosciences Inc.

Provide P/FCFE
for Sagimet Biosciences Inc.

Provide P/B
for Sagimet Biosciences Inc.

Provide EV/S
for Sagimet Biosciences Inc.

Provide EV/GP
for Sagimet Biosciences Inc.

Provide EV/EBITDA
for Sagimet Biosciences Inc.

Provide EV/EBIT
for Sagimet Biosciences Inc.

Provide EV/OCF
for Sagimet Biosciences Inc.

Provide EV/FCFF
for Sagimet Biosciences Inc.

Provide EV/IC
for Sagimet Biosciences Inc.

Show me price targets
for Sagimet Biosciences Inc made by professional analysts.

What are the Revenue projections
for Sagimet Biosciences Inc?

How accurate were the past Revenue estimates
for Sagimet Biosciences Inc?

What are the Net Income projections
for Sagimet Biosciences Inc?

How accurate were the past Net Income estimates
for Sagimet Biosciences Inc?

What are the EPS projections
for Sagimet Biosciences Inc?

How accurate were the past EPS estimates
for Sagimet Biosciences Inc?

What are the EBIT projections
for Sagimet Biosciences Inc?

How accurate were the past EBIT estimates
for Sagimet Biosciences Inc?

Compare the revenue forecasts
for Sagimet Biosciences Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Sagimet Biosciences Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Sagimet Biosciences Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Sagimet Biosciences Inc compared to its peers.

Compare the P/E ratios
of Sagimet Biosciences Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Sagimet Biosciences Inc with its peers.

Analyze the financial leverage
of Sagimet Biosciences Inc compared to its main competitors.

Show all profitability ratios
for Sagimet Biosciences Inc.

Provide ROE
for Sagimet Biosciences Inc.

Provide ROA
for Sagimet Biosciences Inc.

Provide ROIC
for Sagimet Biosciences Inc.

Provide ROCE
for Sagimet Biosciences Inc.

Provide Gross Margin
for Sagimet Biosciences Inc.

Provide Operating Margin
for Sagimet Biosciences Inc.

Provide Net Margin
for Sagimet Biosciences Inc.

Provide FCF Margin
for Sagimet Biosciences Inc.

Show all solvency ratios
for Sagimet Biosciences Inc.

Provide D/E Ratio
for Sagimet Biosciences Inc.

Provide D/A Ratio
for Sagimet Biosciences Inc.

Provide Interest Coverage Ratio
for Sagimet Biosciences Inc.

Provide Altman Z-Score Ratio
for Sagimet Biosciences Inc.

Provide Quick Ratio
for Sagimet Biosciences Inc.

Provide Current Ratio
for Sagimet Biosciences Inc.

Provide Cash Ratio
for Sagimet Biosciences Inc.

What is the historical Revenue growth
over the last 5 years for Sagimet Biosciences Inc?

What is the historical Net Income growth
over the last 5 years for Sagimet Biosciences Inc?

What is the current Free Cash Flow
of Sagimet Biosciences Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Sagimet Biosciences Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Sagimet Biosciences Inc

Balance Sheet Decomposition
Sagimet Biosciences Inc

Current Assets 157.2m
Cash & Short-Term Investments 152.5m
Other Current Assets 4.7m
Non-Current Assets 17.6m
Long-Term Investments 17.5m
PP&E 114k
Current Liabilities 4.1m
Accounts Payable 1.2m
Accrued Liabilities 2.9m
Other Current Liabilities 11k
Efficiency

Earnings Waterfall
Sagimet Biosciences Inc

Revenue
0 USD
Operating Expenses
-26.4m USD
Operating Income
-26.4m USD
Other Expenses
3.6m USD
Net Income
-22.8m USD

Free Cash Flow Analysis
Sagimet Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

SGMT Profitability Score
Profitability Due Diligence

Sagimet Biosciences Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

20/100
Profitability
Score

Sagimet Biosciences Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

SGMT Solvency Score
Solvency Due Diligence

Sagimet Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Sagimet Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SGMT Price Targets Summary
Sagimet Biosciences Inc

Wall Street analysts forecast SGMT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SGMT is 33.25 USD with a low forecast of 6.06 USD and a high forecast of 70.35 USD.

Lowest
Price Target
6.06 USD
27% Upside
Average
Price Target
33.25 USD
599% Upside
Highest
Price Target
70.35 USD
1 378% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SGMT?

Click here to dive deeper.

Dividends

Sagimet Biosciences Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SGMT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SGMT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Sagimet Biosciences Inc Logo
Sagimet Biosciences Inc

Country

United States of America

Industry

Biotechnology

Market Cap

153.2m USD

Dividend Yield

0%

Description

Sagimet Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Mateo, California and currently employs 10 full-time employees. The company went IPO on 2023-07-14. Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). In addition to NASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase II clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.

Contact

CALIFORNIA
San Mateo
155 Bovet Rd., Suite 303
+16505618600
sagimet.com

IPO

2023-07-14

Employees

10

Officers

Executive Chairman of the Board
Dr. George W. Kemble Ph.D.
CEO, President & Director
Mr. David A. Happel
Chief Medical Officer
Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D.
Co-Founder
Dr. Lucas Pelkmans Ph.D.
CFO & Principal Accounting Officer
Mr. Thierry Chauche
General Counsel & Chief Compliance Officer
Ms. Elizabeth Rozek Esq., J.D.
Show More
Senior Vice President of Research & Development
Dr. Marie O'Farrell Ph.D.
Senior Vice President of New Products
Mr. Robert D'Urso
Show Less

See Also

Discover More
What is the Intrinsic Value of one SGMT stock?

The intrinsic value of one SGMT stock under the Base Case scenario is 3.12 USD.

Is SGMT stock undervalued or overvalued?

Compared to the current market price of 4.76 USD, Sagimet Biosciences Inc is Overvalued by 34%.

Back to Top